227 results about "Salbutamol" patented technology

Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating cystic fibrosis or a symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered fluids optionally in combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). Particular embodiments comprise use and / or synergy with tobramycin for treating bacterial infection, and use and / or synergy with a bronchiodilator. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (like, membrane receptors, including but not limited to G protein coupled receptors, and intercellular junctions).

Particular aspects provide electrokinetically-generated fluids (e.g., electrokinetically-generated gas-enriched fluids and solutions), and therapeutic compositions and methods comprising use thereof in treating at least one symptom of cystic fibrosis. In particular embodiments, at least one symptom of cystic fibrosis treated by the present invention include inhibition of Pseudomonas infection, synergy with tobramycin (including TOBI) for use against bacterial infection, and synergy with a bronchiodilator. In particular embodiments, the electrokinetically-generated fluids or therapeutic compositions and methods comprise combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). In certain aspects, the methods comprise regulating or modulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G protein coupled receptors, and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).

Aerosol formulations substantially free of chlorofluorocarbons, for oral and / or nasal administration are described. The formulations comprise 1,1,1,2 tetrafluoroethane, a medicament, optionally an excipient and optionally a surfactant. Methods of treatment utilizing the formulations also are described.

The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.

A method is disclosed utilizing an optically pure eutomer of salbutamol for reducing body fat and / or body weight in mammals and birds. A food composition including the eutomer is also disclosed.

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.

The present invention discloses an oral solid preparation containing ambroxol hydrochloride and salbutamol active components. It is formed from ambroxol hydrochloride, salbutamol and auxiliary material according to a certain mixing ratio. Said oral solid preparation has the obvious synergistic action for remitting the symptoms of dyspnea, etc. due to respiratory tract obstruction diseases of bronchial asthma, chronic bronchitis and pulmonary emphysema, etc.

Stabilized albuterol compositions are provided. The compositions are aqueous inhalation compositions containing albuterol; a buffer, such as citric acid; and a metal chelator, such as EDTA.

The invention relates to a clenobuterol hydrochloride, salbutamol and paylean three joint inspection card and a method for processing a detecting sample, and belongs to the technical field of detection of a beta-receptor stimulating agent, wherein a test strip is arranged inside a shell of the three joint inspection card, and the clenobuterol hydrochloride, salbutamol and paylean three joint inspection card is formed by the adhesion of a sample gasket, a colloidal gold membrane, a cellulose nitrate membrane and a water absorbing membrane to a bearing backboard in turn; the colloidal gold membrane is a glass fiber membrane of a colloidal gold marker containing a clenobuterol hydrochloride antibody, a salbutamol antibody and a paylean antibody; three detection strips are arranged on the cellulose nitrate membrane and contain clenobuterol hydrochloride protein conjugate, salbutamol protein conjugate and paylean protein conjugate respectively; and a quality control strip containing an anti-rabbit antibody or an anti-mouse antibody is arranged. The clenobuterol hydrochloride, salbutamol and paylean three joint inspection card has the advantages of simultaneously detecting the clenobuterol hydrochloride, the salbutamol and the paylean in urine or feed, animal tissue, meat and liver. The inspection card is easy to prepare and quick and convenient to use, saves the detection cost, and has accurate result.

The present invention discloses a method for enriching clenbuterol, ractopamine and salbutamol in a urine sample of breeding livestock, and relates to the field of analytical chemistry, particularly to a sample pretreatment method. The method comprises: carrying out a sample pretreatment, adding sulfonic group surface-modified polystyrene superparamagnetic nanometer beads or sub-micron beads to adsorb, carrying out elution, and collecting the eluent, wherein the elution solution can be directly used for liquid chromatography-mass spectrometry to quantitatively analyze contents of clenbuterol, ractopamine and salbutamol. The method has characteristics of simple operation process, high extraction recovery rate, less elution solvent use amount, and no requirement of rotary evaporation.

The invention discloses an immunochromatography kit for fluorescence quantitative detection of salbutamol and a preparation method of a fluorescence labeling liquid. The kit comprises a test strip and a fluorescence labeling liquid, wherein the test strip is formed by sequentially lapping and sticking a sample pad, a nitrocellulose coating film and absorbent paper on a bottom plate; the nitrocellulose coating film comprises a detection area and a quality control area; the detection area is coated with an SAL-BSA conjugate; the quality control area is coated with anti-rabbit IgG; and the fluorescence labeling liquid contains a fluorescence labeling SAL antibody and a fluorescence labeling rabbit IgG. Compared with an immune colloidal gold labeling test strip, the kit disclosed by the invention has the advantages of higher sensitivity, accurate quantification and the like; and the operation is faster and more convenient than that of an enzyme coupling method.

Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or symptoms thereof (e g, asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (CaPO) and CaPO-associated conditions (e g, bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, in-fluenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) comprising administering a therapeutic composition comprising at least one electrokinetically altered fluid comprising an ionic aqueous solution of charge-stabilized oxygen containing nanostructures as disclosed herein, or comprising administering a nonelectrokinetic superoxygenated aqueous solution The methods preferably comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e g, membrane receptors, (e g, G protein-coupled receptors, and intercellular junctions)) Additional aspects include therapeutic compositions, and combination treatment methods comprising administration of electrokinetically generated fluid in combination with at least one additional therapeutic agent (e g, albuterol, etc).

The invention relates to combinations of an aminosugar and a beta-2-adrenoceptor agonist, such as salbutamol, for the treatment of diseases associated with hypersensivity and inflamation, in particular hypersensivity skin diseases. The aminosugar is preferably a monosaccharide derivative.

The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.

The invention provides a group of oligonucleotide aptamers Apt-1, Apt-2 and Apt-3 which are capable of simultaneously identifying clenbuterol hydrochloride and salbutamol, an oligonucleotide aptamer CLB-2 which is capable of identifying the clenbuterol hydrochloride with high specificity, an oligonucleotide aptamer SAL-5 which is capable of identifying the salbutamol with high specificity and two oligonucleotide aptamers RAC-5 and RAC-6 which are capable of identifying ractopamine with high specificity. Through an SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology based on Fe3O4 magnetic nanoparticle separation, a random oligonucleotide library is immobilized on avidin-enveloped magnetic nanoparticles by virtue of a complementary chain of a biotinylation marker, and the oligonucleotide aptamers, which are high in specific affinity, are finally obtained by conducting screening by 16 turns. The aptamers are broad in application prospect; and the aptamers, by virtue of marker function genes or fluorescent dyes, are applicable to detection of the clenbuterol hydrochloride, the salbutamol and the ractopamine in food; therefore, a new choice is provided for existing detection methods which depend on antibodies.

The invention discloses a preparation method of an electrochemical immunosensor for detecting salbutamol quickly, which belongs to the technical field of chemical detection. In the preparation method, a glassy carbon electrode is modified by carbon nanotubes, polythionine and nano gold in turn, and the electrochemical immunosensor is obtained by a self-assembly process. The invention can prepare the electrochemical immunosensor which has high sensitivity and stability and can detect salbutamol on site quickly.

The invention discloses a synthesis method of a specific salbutamol artificial antigen, belonging to the technical field of biological chemical engineering. The synthesis method disclosed by the invention comprises the following steps of: activating salbutamol through a formaldehyde solution, and connecting 6-aminocaproic acid in the ortho-position of a phenolic hydroxyl group to obtain a salbutamol hapten; and coupling a carboxyl group on the salbutamol hapten with an amino group on a carrier protein to obtain the salbutamol artificial antigen. The synthesis method disclosed by the invention can make up for the insufficiencies and defects of the existing salbutamol antigen synthesis technologies, the salbutamol artificial antigen with high specificity is obtained, the specificity of a produced antibody is high, and the sensitivity is high; and experimental results show that the antiserum titre of an animal immunized by using the salbutamol artificial antigen disclosed by the invention can achieve 80000, the detection limit is 0.5ng / mL, and the half-inhibitory concentration IC50 is 5ng / mL. The antigen or the antibody disclosed by the invention can be used for establishing an enzyme-linked immunosorbent analytical method and a colloidal gold test strip rapid assay method so as to rapidly detect the residues of the salbutamol in a food and further realize broad application prospects.

The invention discloses a particle used for detection of a veterinary drug micromolecule. The particle comprises a receptor particle and a donor particle and is prepared through the following steps: marking carrier protein with a veterinary drug molecule; coupling the veterinary drug molecule-marked veterinary drug with a homogeneous chemiluminescent receptor ball; and preparing a homogeneous chemiluminescent receptor ball coupled with a veterinary drug molecule antibody. The invention further discloses a one-step homogeneous chemiluminescent method for detection of the micromolecule with the particle. The one-step homogeneous chemiluminescent method is used for homogeneous, rapid and high-sensitivity detection of veterinary drug residue and for testing of the contents of frequently used veterinary drug components in feeds, e.g., clenbuterol, ractopamine, salbutamol and terbutaline.

The invention discloses a new process for synthesizing salbutamol. The process comprises the steps that (1) chloromethylation reaction: reactants namely p-hydroxy benzaldehyde and paraformaldehyde react under an acidic condition to generate a compound 1; (2) hydrolysis reaction: the compound 1 is subjected to hydrolysis reaction under a weakly alkaline condition to generate a compound 2; (3) propylidene protective reaction: dihydroxy of a reactant 2 is subjected to propylidene protection under catalysis of concentrated sulfuric acid; (4) epoxidation reaction: a reactant 3 reacts to obtain a compound 4 by using the effect of strong base under the effects of a ylide reagent and a phase transfer catalyst; (5) aminolysis ring-opening reaction: the compound 4 is heated and refluxed in tert-butylamine, and is subjected to aminolysis ring-opening reaction to obtain a compound 5; (6) hydrolysis de-protective reaction: the compound 5 is subjected to hydrolysis reaction under the acidic condition to obtain salbutamol. The new process disclosed by the invention is mild in reaction condition, easy in purification, and simple and easily-available in raw materials; the total molar yield of the process reaches up to 45%, and the product quality reaches up to more than 99.5%.

The invention provides a method for quantitatively detecting salbutamol by using CdTe quantum dots. The method comprises the following steps: uniformly mixing the CdTe quantum dots with surfaces modified by mercaptoacetic acid with a substance to be detected, namely salbutamol, in a phosphate buffer solution, and then detecting fluorescent strength of a system by adopting a molecular fluorometer to realize trace detection of salbutamol because that in a weakly alkaline solution system, the CdTe quantum dots with the surfaces modified with carboxyl groups having negative charges and target molecules having positive charges, namely salbutamol, form a new compound system through electrostatic interaction so as to cause fluorescence quenching. Detection results show that salbutamol has relatively high sensitivity and a relatively wide linear range against the fluorescence quenching of the CeTe quantum dots, so that the changes in the fluorescent strength of the CdTe quantum dots are used for realizing the quantitative detection of salbutamol; and furthermore, the method for quantitatively detecting salbutamol by using the CdTe quantum dots, provided by the invention, is very simple in experimental operation, the detection time is short and the analysis cost is low.

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.

The invention relates to a ternary detection test bar of beta-stimulants albuterol, clenobuterol hydrochloride and ractopamine and a preparation method thereof. The problem of detecting the beta-stimulants the albuterol, the clenobuterol hydrochloride and the ractopamine simultaneously is solved. A parent material PVC plate is sequentially provided with a diversion glass fiber, a carrier glass fiber, a nitrocellulose membrane and a suction cotton pulp plate from front to back; the diversion glass fiber and the suction cotton pulp plate are covered with membranes; the carrier glass fiber absorbs a monoclonal antibody colloidal gold marker resistant to albuterol protein conjugates, clenobuterol hydrochloride protein conjugates and ractopamine protein conjugates; and the intermediate nitrocellulose membrane is provided with a rabbit anti-mouse polyclonal antibody quality control line and three detection lines which are respectively coated with the albuterol protein conjugates, the clenobuterol hydrochloride protein conjugates and the ractopamine protein conjugates. By the invention, the beta-stimulants the albuterol, the clenobuterol hydrochloride and the ractopamine can be effectively detected simultaneously with convenience, quickness and accurate result.

An orally taken salbutamol able to release active components in the sequence: predefined time lag, fast pulse release, and slow release is composed of a slow-release microsphere containing salbutamol, a coated quick release layer, and a coated time-lagging layer.

The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.75 mg or about 1.5 mg albuterol sulfate.

Disclosed is a method for asymmetrical hydrogen transfer of alpha-imino keton for synthesizing chirality salbutamol which comprises, using 5-acetyl methyl salicylate as raw material, oxidizing with oxidation agent into 5-(1,1-)dihydroxy)-acetyl-2-hydroxybenzoate, then reacting with tert-butylamine, obtaining alpha-imine ketone compound. Then using (S,S)-Ru-TsDPEN or (R,R)-Ru-TsDPEN as catalyst, subjecting the alpha-imine ketone compound to asymmetrical hydrogen migration in formylic acid, triethylamine and inert organic solvent system, thus obtaining the optically pure product of (R) or (S)-5-[2-[(1,1-dimethylethyl)amino]-1-ethoxyl]-2-hydroxybenzoate, finally deoxidizing the (R) or (S)-5-[2[(1,1-dimethylethyl)amino]-1-ethoxyl]-2-hydroxybenzoate to obtain the optically pure (R) or (S) chiral salbutamol.

The invention relates to a levalbuterol hydrochloride orally disintegrating tablet and the preparation method; wherein the levalbuterol hydrochloride orally disintegrating tablet comprises an active pharmaceutical ingredient, the levalbuterol hydrochloride, and pharmaceutical necessities. The pharmaceutical necessities include a disintegrant, a filling agent, a masking agent and a corrective. The raw material ingredients calculated by weight ratio are 0.79-2.5 per cent levalbuterol hydrochloride, 50-60 percent disintegrant, 20-40 per cent filling agent, 1.58-10 per cent masking agent and 10-12 per cent corrective, which are made into the orally disintegrating tablets by direct powder compression process. The tablets of the invention is taken easily without water, disintegrated quickly and takes effect quickly, high in bioavailability, less stimulatory function to gastrointestinal tract, and applicable to prevention and cure of bronchial asthma, asthmatic bronchitis, and bronchospasm of an emphysema patient.

The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.